1. Identification of potential pharmacological chaperones that selectively stabilize mutated Aspartoacylases in Canavan disease.
- Author
-
Poddar NK, Wijayasinghe YS, and Viola RE
- Subjects
- Humans, Molecular Docking Simulation, Enzyme Stability drug effects, Mutation, Missense, Small Molecule Libraries pharmacology, Small Molecule Libraries chemistry, Catalytic Domain, Mutation, High-Throughput Screening Assays, Canavan Disease drug therapy, Canavan Disease genetics, Canavan Disease enzymology, Amidohydrolases genetics, Amidohydrolases antagonists & inhibitors, Amidohydrolases metabolism, Amidohydrolases chemistry
- Abstract
Canavan disease is caused by mutations in the ASPA gene, leading to diminished catalytic activity of aspartoacylase in the brain. Clinical missense mutations are found throughout the enzyme structure, with many of these mutated enzymes having not only decreased activity but also compromised stability. High-throughput screening of a small molecule library has identified several compounds that significantly increase the thermal stability of the E285A mutant enzyme, the most predominant clinical mutation in Canavan disease, while having a negligible effect on the native enzyme. Based on the initial successes, some structural analogs of these initial hits were selected for further examination. Glutathione, NAAG and patulin were each confirmed to be competitive inhibitors, indicating the binding of these compounds at the dimer interface or near the active site of the E285A enzyme. The experimental results were theoretically examined with the help of the docking analysis method. The structure activity-guided optimization of these compounds can potentially lead to potential pharmacological chaperones that could alleviate the detrimental effect of ASPA mutations in Canavan patients., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF